nonivamide has been researched along with Low Back Ache in 2 studies
nonivamide: has effect on sensory neurons
nonivamide : A capsaicinoid that is the carboxamide resulting from the formal condensation of the amino group of 4-hydroxy-3-methoxybenzylamine with the carboxy group of nonanoic acid. It is the active ingredient in many pepper sprays.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Until now, nonivamide/nicoboxil ointment has not been tested in a randomized trial for the treatment of acute non-specific low back pain." | 9.22 | Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial. ( Gaubitz, M; Holm, C; Pisternick-Ruf, W; Richter, E; Schiffer, T; Weiser, T, 2016) |
| "Until now, nonivamide/nicoboxil ointment has not been tested in a randomized trial for the treatment of acute non-specific low back pain." | 5.22 | Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial. ( Gaubitz, M; Holm, C; Pisternick-Ruf, W; Richter, E; Schiffer, T; Weiser, T, 2016) |
| "The aim of the present study was to evaluate the therapeutic potential of local capsaicinoid (EMSPOMA(®) cream) treatment on chronic low back pain in patients with degenerative spine diseases and to investigate the possible mechanism of action of the therapy." | 5.19 | Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma. ( Bagoly, T; Boros, M; Helyes, Z; Horváth, K; Kemény, A; Kilár, F; Pintér, E; Sándor, V; Szolcsányi, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horváth, K | 1 |
| Boros, M | 1 |
| Bagoly, T | 1 |
| Sándor, V | 1 |
| Kilár, F | 1 |
| Kemény, A | 1 |
| Helyes, Z | 1 |
| Szolcsányi, J | 1 |
| Pintér, E | 1 |
| Gaubitz, M | 1 |
| Schiffer, T | 1 |
| Holm, C | 1 |
| Richter, E | 1 |
| Pisternick-Ruf, W | 1 |
| Weiser, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre, Double-blind, Randomised, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Topically Applied Hyperemisation-inducing Ointment (2cm Ointment Line Per Application; up to 3 Times Daily for up to 4 Days) Containing 2[NCT01708915] | Phase 3 | 805 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Average pain intensity was assessed in the evening of days 1, 2, 3 and 4 on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible). The last individual treatment day is the last day with diary-recorded ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 1 to 4 days
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.884 |
| Nicoboxil | -2.371 |
| Nonivamide | -3.074 |
| Nicoboxil/Nonivamide | -3.540 |
Pain intensity was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3 and 4 hours after first ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 4 hours after first ointment application
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.650 |
| Nicoboxil | -0.968 |
| Nonivamide | -1.641 |
| Nicoboxil/Nonivamide | -1.699 |
Pain intensity (PI) was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3, 4, 6 and 8 hours after first ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 8 hours after first ointment application
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.049 |
| Nicoboxil | -1.428 |
| Nonivamide | -2.252 |
| Nicoboxil/Nonivamide | -2.410 |
Patient assessment of efficacy was assessed on a 4-point verbal rating scale (VRS, 0 = 'poor', 1 = 'fair', 2 = 'good', 3 = 'very good' relief of the patients' low back pain) in the evening of days 1, 2, 3 and 4. The last individual treatment day is the last day with diary-recorded ointment application (NCT01708915)
Timeframe: 1 to 4 days
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Very good | Good | Fair | Poor | Missing | |
| Nicoboxil | 19 | 67 | 20 | 94 | 1 |
| Nicoboxil/Nonivamide | 50 | 88 | 20 | 42 | 2 |
| Nonivamide | 34 | 85 | 27 | 52 | 0 |
| Placebo | 9 | 47 | 22 | 125 | 1 |
2 trials available for nonivamide and Low Back Ache
| Article | Year |
|---|---|
Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma.
Topics: Administration, Cutaneous; Aged; Analgesics; Capsaicin; Female; Humans; Low Back Pain; Male; Middle | 2014 |
Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial.
Topics: Acute Pain; Adolescent; Adult; Aged; Capsaicin; Double-Blind Method; Drug Combinations; Female; Huma | 2016 |